Introduction
============

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by hemolytic anemia and thrombocytopenia often complicated by acute renal failure in children.[@b1-ijnrd-3-085] Both typical or diarrhea-associated HUS form is associated with infection by *Escherichia coli* and has a good prognosis.[@b2-ijnrd-3-085] A second less common from, termed atypical, nondiarrhea-associated HUS (aHUS) is a heterogeneous recurrent disorder which displays high mortality and morbidity.[@b3-ijnrd-3-085] This form can occur at any age with familial and sporadic cases. HUS is defined as familial when at least two members of the same family are affected by the disease at least 6 months apart. Familial aHUS exists in patterns of both autosomal dominant and recessive inheritance.[@b4-ijnrd-3-085] Triggers for the sporadic form include infection with human immunodeficiency virus, cancer, use of immunotherapeutic agents, diseases and pregnancy.[@b3-ijnrd-3-085] However, approximately 50% of sporadic cases appear to be idiopathic.[@b4-ijnrd-3-085]

It has recently been shown that aHUS is associated with mutations in the complement regulatory protein factor H (FH).[@b5-ijnrd-3-085]--[@b8-ijnrd-3-085] The FH gene is located on chromosome 1q32 within a cluster of genes encoding the regulatory complement components of the activation of C3.[@b9-ijnrd-3-085] These genes encode proteins, which consist of multiple homologous modules called "complement control protein modules" (CCPs), previously known as short consensus repeats (SCRs).[@b10-ijnrd-3-085] Each SCR is 60 amino acids in length and has four cysteine residues which form two disulphide bridges: Cys1--Cys3 and Cys2--Cys4. These disulfide bridges are important in maintaining the characteristic structure of the SCR module.[@b11-ijnrd-3-085]

The 155Kd fluid phase glycoprotein FH, is composed of 20 SCRs each encoded by a single exon, with the exception of the second SCR encoded by exon 2a and 2b.[@b12-ijnrd-3-085] It regulates the alternative pathway (AP) by competing with factor B for binding to C3b and acting as a cofactor for factor I, leading to proteolytic inactivation of C3b.[@b13-ijnrd-3-085],[@b14-ijnrd-3-085] Factor H can also interact with polyanionic molecules (sialic acids or glycosaminoglycans) on certain cellular surfaces conferring to them a resistance to damage as a consequence of complement activation through the AP.[@b15-ijnrd-3-085]

In order to identify potential FH mutations predisposing to aHUS, we performed a protein and genetic analysis of FH within two Tunisian families presenting a diagnostic suspicion of aHUS.

Materials and methods
=====================

Patients
--------

Patients were recruited from the Pediatric department of Mahdia Hospital in Central Tunisia.

### Family A pedigrees and case histories are shown in [Figure 1](#f1-ijnrd-3-085){ref-type="fig"}

The family exhibited a high grade of consanguinity.

### Patient I-4

A 25-day-old Tunisian boy with a family history of the death of a brother (I-2) and four cousins (I-5, I-6, I-7 and I-8) ([Table 1](#t1-ijnrd-3-085){ref-type="table"}) by HUS confirmed by postmortem renal biopsy presented initially with pallor, fever, refusal to suckle, and vomiting, but without any notion of diarrhea. A clinical examination found tachypnea, lethargy, a temperature of 39.6°C, and hypertension (blood pressure was 120/80 mmHg), with evidence of fluid overload. Initial investigations performed were as follows: a severe anemia with hemoglobin level of 5.9 g/dL, platelet count of 140000/mm^3^, schistocytosis at 16%, hematuria and proteinuria (3.3 g/day). The blood level of urea was 16 mM/L and the glomerular filtration rate, estimated using the Cockcroft--Gault equation for creatinine clearance (eGFR) was 41 mL/min/1.73 m^2^. A diagnosis of atypical hemolytic uremia (aHUS) was established. A renal biopsy was performed and disclosed a pattern of thrombotic microangiopathy predominantly in the glomeruli with few vascular lesions. At this stage, he was transfused by leukocyte-depleted red blood cells. Administration of 2000 mL fresh frozen plasma (FFP) was undertaken for seven consecutive days associated with intravenous furosemide at maximal dose (2 mg/kg/day) and antihypertensive therapy was achieved with intravenous nicardipine (1 mg/kg/day). An adequate control was gained 20 days later using the same oral drugs with a normal renal function. A relapse occurred 6 months later, with acute renal failure that required peritoneal dialysis and fresh frozen plasma administration for 10 days. The patient regained independent renal function. At the time of writing, 2 years after onset, his renal function has remained normal with twice-monthly plasma infusions and no relapse of hemolysis has occurred.

### Patient I-2

This 5-month-old Tunisian boy was referred for anemia (hemoglobin level of 4.9 g/dL), thrombocytopenia (platelet count of 100000/mm^3^) and acute renal failure (creatinine clearance was 41 mL/min/1.73 m^2^), leading to death at day 2 despite standard therapy and plasma infusions. Analysis of post-mortem renal biopsy material revealed ischemic glomeruli and fibrotic lesions in arteria and interstitium without deposition of C3.

### Patients I-5, I-6, I-7, and I-8

These children, who were brothers and first cousins of patients I-2 and I-4, were referred to pediatric center for rapidly progressive renal failure, hypertension since the age of 52, 15, and 25 days, respectively ([Table 1](#t1-ijnrd-3-085){ref-type="table"}). Although, combining diuretics and angiotensin-converting enzyme inhibitors treatment, the clinical progression was critical with the rapid death of patients I-6, I-7, and I-8 a few days after admission and before the use of peritoneal dialysis. At the acute phase, patient I-5 had also received a transfusion of packed red blood cells, plasma-exchanges and intravenous antihypertensive therapy. He regained independent renal function (creatinine clearance: 50 mL/min/1.73 m^2^) ten days after the initial episode. However, a recurrence of HUS 5 days later required weekly administration of FFP for a period of 2 months. Following acute otitis at the age 4 months, the child was referred for another episode of HUS. Despite the standard therapy, he died 48 hours after hospitalization. Analysis of post-mortem renal biopsy specimens revealed the presence of severe thrombotic microangiopathy lesions.

### Family B pedigrees and case histories

This second family had the same geographic origin as the first family. No complement exploration could be performed for patient's I-1 and I-2. Only five healthy members were serologically investigated and genotyped ([Figure 1](#f1-ijnrd-3-085){ref-type="fig"}).

### Patient I-1

A 6-month-old Tunisian boy, born to high grade-consanguineous parents was referred with a history of fever and gross hematuria without diarrhea prodromal. The patient exhibited anemia with hemoglobin level of 7.9 g/dL, thrombocytopenia (platelet count of 140000/mm^3^), renal insuff iciency (creatinine clearance: 38 mL/min/1.73 m^2^) and hypertension (120/80 mmHg). While receiving diuretics and intravenous antihypertensive therapy, the children died abruptly and the postmortem renal biopsy showed ischemic shrinkage of the capillaries with lesions of thrombotic microangiopathy.

### Patient I-2

This Tunisian girl was presented with atypical HUS at the age of 18 months with rapidly critical clinical progression and death just a few hours after admission and before the use of peritoneal dialysis. Analysis of postmortem renal biopsy material revealed the same thrombotic microangiopathy lesions as her brother I-1 ([Table 1](#t1-ijnrd-3-085){ref-type="table"}).

Controls
--------

One hundred fifty healthy controls matched for sex, ethnic, and geographic origin were also studied. Medical examination and a questionnaire were performed for all controls. Exclusion criteria were HUS in the donor or in a first-degree relative.

Patients and controls received detailed information on the purpose of the study. It was approved by the local ethics committee and *a priori* consent was obtained from all subjects.

Materials
=========

Complement assays
-----------------

Measurement of total hemolytic complement (CH50) and alternative pathway (AP50) activities in EDTA samples were determined using the method of Mayer.[@b16-ijnrd-3-085] Plasma concentrations of C4, C3, and Factor B (FB) antigens were measured by nephelometry (Minineph™; The Binding Site, Birmingham, UK). Plasma levels of the third and/or fourth complement component below the lower limit of normal ranges ([Table 2](#t2-ijnrd-3-085){ref-type="table"}), defined as mean ± 2 standard deviations (SD) were taken to indicate hypocomplementemia.

Serum samples were used to quantify Factor H antigen concentration by enzyme-linked immunosorbent assay (ELISA) assay, described previously by Dragon-Durey.[@b17-ijnrd-3-085] Normal ranges were 100% ± 30% as calculated by the results from 100 healthy individual donors.

Genomic FH DNA sequencing
-------------------------

Genomic DNA was amplified by means of polymerase chain reaction (PCR) using nucleotides flanking each exon. For all patients, all 22 FH exons were sequenced and analyzed. The number of nucleotide or codon referenced is indicated according to Warwicker and colleagues.[@b5-ijnrd-3-085]

### Prediction of effects of amino acid substitutions

The PolyPhen server (see <http://www.bork.embl-heidelberg.de/PolyPhen/>) was used to predict the likely impact of non-synonymous amino acid substitutions or deletions, observed in patients and controls.

Results
=======

Complement component assessment
-------------------------------

Plasma complement profiles at the time of diagnosis are listed in [Table 2](#t2-ijnrd-3-085){ref-type="table"}. Results of complement investigation were confirmed at least twice.

### Family A

Patient I-4 exhibited severe complement consumption through the alternative pathway, as indicated by very low plasma levels of CH50, AP50, C3, and FB. This patient presented a plasma concentration of FH protein below 1%. These results are in concordance with homozygous FH deficiency.

Plasma complement profile measurement showed mildly decreased CH50 and AP50, low C3 and FB plasma levels in patients' I-1, I-3, I-10, II-6, II-7, II-12, II-13, III-5, and III-7. Antigenic plasma levels of FH were between 35% and 50% of normal values, suggesting heterozygous FH deficiency.

### Family B

In all the investigated healthy members a FH antigenic level and C3 and FB plasma levels were normal.

Characterization of the genetic defect
--------------------------------------

### Family A

Genomic sequencing showed a four-bp TAGA or ATAG deletion in SCR 20 of factor H, between nucleotides of 3767 and 3770, as a homozygous state in the patient (I-4) and a heterozygous state in the parents; and all family members carried heterozygous FH deficiency ([Figure 2](#f2-ijnrd-3-085){ref-type="fig"}). This mutation leads to the loss of the normal stop codon (TAG) inducing a frame shift in factor H coding sequence. The predicted protein sequence shows 37 additional amino acid changes induced by this deletion.

### Family B

A nucleotide substitution G to C at position 3617 resulting in an arginine/threonine heterozygous nonsense mutation at 1182 codon from SCR 20 was detected in the father (II-1). The predictive translation shows that this nucleotide substitution induced structural change in the hypervariable loop of SCR-20 between strands β2 and β3. However, the healthy mother (II-2) and brothers (I-3, I-4, I-5) do not exhibit the same substitution.

Controls
--------

Both molecular deletion and nucleotide substitution were not found in 150 Tunisian healthy controls or reported in other control populations and thus are unlikely to represent allelic variants.

Discussion
==========

FH deficiencies have been reported in both homozygous and heterozygous forms associated with aHUS and other kidney diseases such as type II or III membranoproliferative glomerulonephritis.[@b8-ijnrd-3-085] Genetic studies have found several missense mutations between SCR16 and SCR20 suggesting a particular role of the C-terminal domains of the FH protein.[@b18-ijnrd-3-085]--[@b22-ijnrd-3-085] This region is important for binding to C3b and sialic acid residues on to cell surfaces. Mutations in this region, therefore, impair the ability of factor H to protect against complement-mediated host cell damage which may cause the vascular injury observed in HUS.[@b18-ijnrd-3-085] In a complete FH deficient proband we have identified a molecular abnormality consisting of a 4-bp TAGA or ATAG deletion leading to a normal stop codon loss and inducing a longer protein with 37 additional amino acids. According to the family tree, whoever has a high degree of consanguinity, this deletion is transmitted in an autosomal recessive form. The conformational change could explain the production of a macromolecule unable to be secreted or quickly hydrolyzed. We speculate that this hypothesis explains the total deficiency of the H protein in our present case. It also could explain the partial deficiency of the FH antigen level in heterozygous members. Protein crystallography and immunohistochemical analyses are necessary to clarify the molecular mutant protein synthesis, as well as its cellular secretion.

This genetic abnormality has been previously described by Sellier-Leclerc[@b23-ijnrd-3-085] and Sethi[@b24-ijnrd-3-085] who report FH antigenic level at 4% and 10% respectively. Sethi and colleagues[@b24-ijnrd-3-085] have not detected by Western blot the abnormal protein in serum, suggesting an impairment of the secretion of this FH protein would be retained in the cytoplasm. Also, Neumann[@b7-ijnrd-3-085] described a deletion of four nucleotides AGAA at a position 3768 of the nucleotide sequence inducing the same frameshift consequences. Several therapies, such as plasma administration and plasma exchanges were used in patients with aHUS in order to supplement factor H deficiencies.[@b25-ijnrd-3-085] However, a combined liver-kidney transplantation was required in case of the progression to end-stage renal disease.[@b26-ijnrd-3-085] In all the cases described by Sellier-Leclerc,[@b23-ijnrd-3-085] Sethi[@b24-ijnrd-3-085] and Neumann,[@b7-ijnrd-3-085] patients exhibited the evolution chronic kidney disease and awaited a renal transplantation.

To date, while the FH antigenic level was below than 1%, the renal function of our present case remains normal under regularly plasma infusions. This clinical course is also extremely different from that observed in his brother and the first cousins both of whom died abruptly, despite standard therapy. The results of our data suggests that the genetic predisposition to complement FH dysregulation was perhaps due to a trigger event such as infection or a second susceptibility factor which has not yet been identified.

Other genetic abnormalities involved in the impairment of intrachain disulfide bonds leading to the change of the secondary structure of the protein were also described.[@b17-ijnrd-3-085] Similar mutations involving a cysteine in SCR 9 and 16 were previously reported by Ault[@b27-ijnrd-3-085] and Schmidt[@b28-ijnrd-3-085] and it has been demonstrated that the 150-kD protein was retained in the intracellular fraction. In our data, such mutations were not detected.

Several studies have shown that many patients had a functionally significant mutation in the absence of alternative pathway consumption.[@b21-ijnrd-3-085] Consequently, and despite the normal C3 and factor H levels, we processed to CFH mutation screening in the family B. A single heterozygous base pair substitution at 1182 codon involving an arginine (Arg) that was changed to a threonine (Thr) was found in the father. Nuclear magnetic resonance and chemical shift mapping indicated that Arg1182 is one of the eight residues involved in heparin binding.[@b29-ijnrd-3-085],[@b30-ijnrd-3-085] The majority of mutations that occur within, or close proximity to, this loop show a type II phenotype (in which serum levels of factor H are normal).[@b31-ijnrd-3-085],[@b32-ijnrd-3-085]

In our data, we report two genetically different abnormalities in aHUS consanguineous families. The mechanisms by which these factor H mutations lead to this disease are not fully understood. Further biochemical and functional studies will provide deeper insights into the pathogenesis of aHUS.
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![Pedigrees of family 1 and 2: Solid circles and squares represent respectively female and male members.](ijnrd-3-085f1){#f1-ijnrd-3-085}

![DNA sequencing for a section of factor H SCR20 in family A.\
**Notes: A**) Wild type chromatogram, **B**) Chromatogram of I--4 patient: After the nucleotides AAAAAGA, there is a deletion of 4 nucleotides TAGA (3767_3771delTAGA), **C**) Chromatogram of a heterozygous patient with superposed peaks from the wild-type and mutant alleles.](ijnrd-3-085f2){#f2-ijnrd-3-085}

###### 

Case histories of families A and B

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Family**   **Subject**   **Status/Disease**   **Onset of disease**   **Clinical features**                                      **Treatments**            **Disease outcome**
  ------------ ------------- -------------------- ---------------------- ---------------------------------------------------------- ------------------------- -----------------------------------------
  A            I-1           Unaffected           --                     --                                                         --                        --

  A            I-2           Affected/HUS         5 months               Severe hypertension dyspnea, anemia\                       Plasma infusions\         Death 2 days after onset
                                                                         Acute pulmonary edema                                      Antihypertensives         

  A            I-3           Unaffected           --                     --                                                         --                        --

  A            I-4           Affected/HUS         25 days                Severe hypertension edema, anemia\                         Plasma infusions\         Relapse 6 months after diagnosis\
                                                                         Renal failure refusal to suckle, proteinuria, hematuria    Peritoneal dialysis\      Currently, normal renal function
                                                                                                                                    Antihypertensive agents   

  A            I-5           Affected/HUS         52 days                Renal failure\                                             Plasma infusions\         One recurrence 15 days after diagnosis\
                                                                         Severe hypertension\                                       Antihypertensive agents   Death 4 months after diagnosis
                                                                         Anemia heart failure proteinuria, hematuria                                          

  A            I-6           Affected/HUS         15 days                Renal failure\                                             Plasma infusions\         Death 3 days after diagnosis
                                                                         Severe hypertension\                                       Antihypertensive agents   
                                                                         Anemia proteinuria, hematuria                                                        

  A            I-7           Affected/HUS         25 days                Renal failure\                                             Plasma infusions\         Death 12 days after diagnosis
                                                                         Severe hypertension pneumonia\                             Antihypertensive agents   
                                                                         Anemia proteinuria, hematuria                                                        

  A            I-8           Affected/HUS         25 days                Renal failure\                                             Plasma infusions\         Death 12 days after diagnosis
                                                                         Severe hypertension\                                       Antihypertensive agents   
                                                                         Vomiting\                                                                            
                                                                         Anemia proteinuria, hematuria                                                        

  A            I-9           Unaffected           --                     --                                                         --                        --

               I-10                                                                                                                                           

  A            II-6          Unaffected           --                     --                                                         --                        --

               II-7                                                                                                                                           

               II-8                                                                                                                                           

  A            II-12         Unaffected           --                     --                                                         --                        --

               II-13                                                                                                                                          

  A            III-1         Unaffected           --                     --                                                         --                        --

               III-5                                                                                                                                          

               III-7                                                                                                                                          

  B            I-1           Affected/HUS         6 months               Renal failure\                                             Plasma infusions\         Death 24 hours after diagnosis
                                                                         Severe hypertension heart failure proteinuria, hematuria   Antihypertensive agents   

  B            I-2           Affected/HUS         18 months              Renal failure\                                             Plasma infusions\         Death 12 hours after diagnosis
                                                                         Severe hypertension\                                       Antihypertensive agents   
                                                                         Vomiting\                                                                            
                                                                         Anemia proteinuria, hematuria                                                        

  B            I-3           Unaffected           --                     --                                                         --                        --

               I-4                                                                                                                                            

               I-5                                                                                                                                            

               I-6                                                                                                                                            

  B            II-1          Unaffected           --                     --                                                         --                        --

               II-2                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Results of complement investigations

  **Family**   **Subject**   **CH50 25--61 U/ml**   **C3 121 ± 36 mg/100 ml**   **C4 26 ± 12 mg/100 ml**   **AP50 100%**   **Factor H 100% ± 30%**   **Factor B 20 ± 11 mg/100 ml**
  ------------ ------------- ---------------------- --------------------------- -------------------------- --------------- ------------------------- --------------------------------
  A            I-1           27                     90                          26.4                       52              50                        10
  A            I-3           29.4                   85                          22.3                       50              50                        8.5
  A            I-4           \<10                   48.3                        15.7                       5               \<1                       8
  A            I-9           27                     100.1                       26                         80              90                        27
  A            I-10          24                     75.3                        14.4                       35              35                        11
  A            II-6          27                     85.5                        87.7                       50              50                        8
  A            II-7          26.3                   82                          24                         50              35                        6.8
  A            II-8          28.1                   131.9                       11.7                       100             100                       27
  A            II-12         15.3                   85.8                        34.1                       50              30                        10
  A            II-13         28.5                   91                          34.1                       35              30                        10
  A            III-1         26.6                   127.9                       24.6                       100             95                        27
  A            III-5         \<10                   86.9                        34.1                       50              35                        8
  A            III-7         14.2                   85.1                        31.6                       50              50                        8
  B            I-3           25                     128.1                       24.5                       80              100                       18
  B            I-4           25                     128.5                       11.8                       50              100                       15
  B            I-5           25                     121.4                       16.9                       52              85                        18
  B            II-1          25                     144.6                       56.2                       50              100                       18
  B            II-2          25                     129.3                       38.9                       100             95                        18
